A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
Authors:
Open Access
- 4 September 2025
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 26 (1) , 46-54
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (UM1 AI106701)
- National Institutes of Health (UM1 AI068636)
- National Institute of Allergy and Infectious Diseases (UM1 AI068634)
- ACT Government
This publication has 31 references indexed in Scilit:
- Treatment Strategy for Rifampin-Susceptible TuberculosisNew England Journal of Medicine, 2023
- Four-Month Rifapentine Regimens with or without Moxifloxacin for TuberculosisNew England Journal of Medicine, 2021
- Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysisThe Lancet, 2018
- A diagnostic tool for population models using non-compartmental analysis: The ncappc package for RComputer Methods and Programs in Biomedicine, 2016
- The association between sterilizing activity and drug distribution into tuberculosis lesionsNature Medicine, 2015
- Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosisProceedings of the National Academy of Sciences, 2015
- Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort studyThe Lancet, 2014
- Comprehensive Treatment of Extensively Drug-Resistant TuberculosisNew England Journal of Medicine, 2008
- Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in South IndiaTubercle, 1990
- A New Series of Phenazines (Rimino-Compounds) With High Antituberculosis ActivityNature, 1957